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Clinical and Epidemiologic Research
Antithrombotic Medication and Incident Open-Angle
Glaucoma
Michael W. Marcus,1 Rogier P. H. M. Mu¨skens,1 Wishal D. Ramdas,2,3 Roger C. W. Wolfs,2,3
Paulus T. V. M. de Jong,2,4,5 Johannes R. Vingerling,3 Albert Hofman,2 Bruno H. C. Stricker,2,6,7
and Nomdo M. Jansonius1,2
PURPOSE. To determine the associations between the use of
antithrombotic drugs and incident open-angle glaucoma
(OAG).
METHODS. Ophthalmic examinations including measurements
of the IOP and perimetry were performed at baseline and
follow-up in 3939 participants of the prospective population-
based Rotterdam Study who did not have OAG at baseline. The
use of antithrombotic drugs was monitored continuously
during follow-up. Antithrombotic drugs were stratified into
anticoagulants and platelet aggregation inhibitors. Associations
between incident OAG and the use of antithrombotic drugs
were assessed using Cox regression; the model was adjusted
for age, sex, baseline IOP and IOP-lowering treatment, family
history of glaucoma, and myopia. Associations between
antithrombotic drugs and IOP at follow-up were analyzed with
multiple linear regression.
RESULTS. During a mean follow-up of 9.8 years, 108 participants
(2.7%) developed OAG. The hazard ratio for anticoagulant use
was 0.90 (95% confidence interval [CI], 0.55–1.48; P ¼ 0.69)
and for platelet aggregation inhibitors 0.80 (0.53–1.21; P ¼
0.28). There was no trend towards a reduced or increased risk
of incident OAG with prolonged anticoagulant use (P value for
trend 0.84) or platelet aggregation inhibitor use (0.59). There
was a significant IOP-lowering effect of anticoagulants (0.31
mm Hg; 95% CI,0.58 to0.04 mm Hg; P¼ 0.025) but not of
platelet aggregation inhibitors (P ¼ 0.06). The IOP-lowering
effect of anticoagulants disappeared after additional adjustment
for the use of systemic beta-blockers.
CONCLUSIONS. Use of anticoagulants or platelet aggregation
inhibitors appears not to be associated with incident OAG.
(Invest Ophthalmol Vis Sci. 2012;53:3801–3805) DOI:
10.1167/iovs.12-9604
Open-angle glaucoma (OAG) is an insidious diseasecharacterized by irreversible loss of retinal ganglion cells
and cupping of the optic disc, ultimately resulting in loss of
sight. The prevalence of OAG in the 40þ population is
approximately 2%.1 An elevated IOP is an important risk factor
for OAG, and the therapeutic management of OAG is currently
targeted towards the lowering of IOP. However, OAG
progression often continues despite an apparently sufficient
reduction of the IOP. As this IOP-independent progression is at
best partially understood, more research is needed to elucidate
the pathogenesis of OAG, which may result in the development
of other therapeutic strategies.
Impaired blood flow has been postulated to be involved in
the pathogenesis of OAG.2,3 Treatment with antithrombotic
drugs such as anticoagulants and platelet aggregation inhibitors
(PAIs) is a frequently used prophylaxis against impaired blood
flow.4 Moreover, PAIs have been suggested to have neuropro-
tective properties.5 Some clinicians already prescribe PAIs
based on the ‘‘it doesn’t hurt to try’’ principle. However, two
recent trials in Alzheimer’s disease (like OAG, a neurodegener-
ative disease) showed no effect of a PAI (aspirin) on cognitive
functioning, yet it increased the risk of serious bleeds.6,7 For all
these reasons, it seems logical to study the potential role of these
drugs in the management of OAG, as suggested earlier.8 Thus far,
one study addressed the effect of PAIs (acetylsalicylic acid, ASA)
on IOP,9 and two studies examined the effect of ASA on the
progression of OAG.10,11 As these studies gave equivocal results
(see Discussion section), another look at this issue seemed
warranted. Moreover, we did not find any study addressing the
effects of anticoagulants or of PAIs other than ASA on OAG.
The aim of this study was to determine the associations
between the use of anticoagulants or PAIs and the develop-
ment of OAG in a prospective population-based cohort study.
METHODS
Study Population
The present study was performed as part of the Rotterdam Study, a
prospective population-based cohort study investigating age-related
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disorders. The study population consisted of 7983 almost exclusively
Caucasians aged 55 years and older living in the Ommoord district of
Rotterdam, the Netherlands.12 For this study, data from a subset of
3939 participants who did not have OAG (see below) at baseline and
who completed at least one follow-up examination were used.
Differences between those who completed at least one follow-up
and those who did not were published earlier.13 The latter were older,
more often female, more often had a history of stroke, and less
frequently reported a positive family history of glaucoma. The baseline
examination took place from 1991 to 1993; follow-up examinations
were performed from 1997 to 1999 and from 2002 to 2006. All
measurements were conducted after the Medical Ethics Committee of
the Erasmus University Rotterdam had approved the study protocol
and all participants had given written informed consent in accordance
with the Declaration of Helsinki.
Ophthalmic Assessment
Participants underwent similar eye examinations at baseline and at the
two follow-up rounds. These examinations included refraction,
measurement of the best-corrected visual acuity, Goldmann applana-
tion tonometry (Haag-Streit AG, Bern, Switzerland), fundoscopy, fundus
photography of the posterior pole, imaging of the optic disc, and visual
field testing.
At each visit, three IOP measurements were taken on each eye, and
the median value of these three measurements was recorded14; the
higher median of both eyes was used in the analysis. The visual field of
each eye was screened using a 52-point suprathreshold test that
covered the central visual field with a radius of 248 (Humphrey Field
Analyzer [HFA]; Carl Zeiss, Oberkochen, Germany).15,16 Visual field
loss was defined as nonresponse to a light stimulus of 6 dB above a
threshold-related estimate of the hill of vision in at least three
contiguous test points, or four including the blind spot. In participants
with reproducible abnormalities on suprathreshold testing, Goldmann
perimetry (Haag-Streit AG; baseline and first follow-up) or full-threshold
HFA 24-2 testing (second follow-up) was performed on both eyes. The
classification processes of the Goldmann perimetry and full-threshold
HFA 24-2 test results have been described in detail before.13,15 In short,
visual field loss was considered to be glaucomatous visual field loss
only if reproducible and after excluding all other possible causes.
Incident Open-Angle Glaucoma
We defined incident OAG as no glaucomatous visual field loss in both
eyes at baseline and glaucomatous visual field loss in at least one eye at
follow-up.13 All identified cases were examined by an experienced
ophthalmologist (PTVMdJ and RCWW) who performed gonioscopy
and a dilated ophthalmic exam. Cases with a history or signs of angle
closure or secondary glaucoma were excluded.
Medication Data
Data on antithrombotic drugs prescriptions for all participants were
obtained from seven pharmacies using a centralized computer network
in the Ommoord district of Rotterdam, The Netherlands, from January 1,
1991, onward. This included the product name, Anatomical Therapeutic
Chemical (ATC) code, duration of use, and the date of first prescription.
Antithrombotic drugs were classified based on ATC system, according to
pharmacologic subgroup, into anticoagulants (B01AA; coumarin
derivatives) and PAIs (B01AC; abciximab, ASA, carbasalate calcium,
clopidogrel, dipyridamole, eptifibatide, prasugrel, tirofiban). The use of
antithrombotics was recorded as the number of days with use during
follow-up. Usage before baseline was not taken into account.
Other Covariables
Other covariables included age, sex, smoking, diabetes mellitus,
cardiovascular diseases, the use of antihypertensive drugs, the use of
statins, body mass index, total cholesterol, IOP, IOP-lowering treat-
ment, family history of glaucoma, and myopia. All these covariables
were measured at baseline. Smoking status was self-reported and
categorized as ‘‘ever’’ or ‘‘never’’ smoker. Data on diabetes mellitus and
cardiovascular disorders such as angina pectoris, atrial fibrillation,
myocardial infarction, heart failure, hypertension, and stroke were
obtained from the participants through interviews, electrocardiogram
readings, and nonfasting and fasting serum blood glucose levels.
Diabetes was defined as the use of antidiabetic medication or by a
nonfasting or post-load plasma glucose level above 200 mg/dL (11.1
mM). Hypertension was defined as the use of antihypertensive
medication for the indication of hypertension or as a systolic blood
pressure of 140 mm Hg or more, or a diastolic pressure of 90 mm Hg or
more. The use of antihypertensive medication and statins was
determined using the pharmacy computer system as described above.
Body mass and height were measured at the research center. Total
serum cholesterol was measured in nonfasting blood. IOP-lowering
treatment was defined as the use of IOP-lowering medication or a
history of glaucoma surgery or laser trabeculoplasty. The family history
of glaucoma was determined by interviews and was considered
positive if the participant reported a history of glaucoma in parents,
siblings, or offspring. Myopia was defined as a spherical equivalent
refractive error of 4 diopters (D) and more myopia.16 Eyes with a
cataract extraction before baseline were excluded from this analysis. In
cases with one eye with incident OAG, the refraction of that eye was
used. In participants without OAG or with OAG in both eyes, the
refraction of a random eye was used.
Statistical Analysis
Differences in baseline characteristics between participants with and
without incident OAG and differences in baseline characteristics
between antithrombotic drug users and nonusers were evaluated using
v2 tests for categorical variables and t-tests for normally distributed
continuous variables. To determine the associations between the use of
antithrombotic drugs and incident OAG, the use of anticoagulants or
PAIs was initially defined as any use during follow-up, and the
associations were initially analyzed with v2 tests. Subsequently, a Cox
proportional hazards model was used to calculate hazard ratios (HR)
and corresponding 95% CI for the associations between the use of
anticoagulants or PAIs and incident OAG. Follow-up duration was used
as the time axis in the model. For participants without incident OAG,
the follow-up duration was counted from the baseline visit to the last
visit with reliable perimetry. For incident OAG cases, the follow-up
ended at the first visit in which glaucomatous visual field loss was
detected. The antithrombotic drugs, age and sex, and other covariables
with P < 0.20 in the univariable comparisons were included in the
multivariate analysis. Subsequently, the antithrombotic drugs, age and
sex, and other covariables with P< 0.05 in the initial multivariate model
were included in the final model. The use of antithrombotic drugs was
entered in the model as any use during follow-up. To allow for the
evaluation of a possible dose–response relationship, we also performed
analysis after making three nominal categories based on the duration of
medication use, being no use, cumulative use during 2 years or less, and
cumulative use during more than 2 years (see Discussion section). The
dose–response relationship was evaluated with a trend test. To explore
direct effects of the antithrombotics on the IOP, we conducted a
multiple linear regression analysis, with IOP at follow-up as the
dependent variable. This analysis was adjusted for IOP-lowering
treatment at follow-up and for the same covariates as the final Cox
model, except for baseline IOP and IOP-lowering treatment at baseline.
All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC).
A P value of 0.05 or less was considered statistically significant.
RESULTS
During a mean follow-up of 9.8 years, 108 participants (2.7%)
developed OAG. Table 1A depicts the baseline characteristics
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of the study population for participants with and without
incident OAG. Participants who developed OAG were older
and more often male, more often had a positive family history
of glaucoma, and more often had myopia. They also had a
higher IOP and more frequently received IOP-lowering
treatment. Table 1B shows the baseline characteristics of the
study population for antithrombotic drug users and nonusers.
Twenty-one of 108 (19.4%) OAG cases and 701 of 3831
(18.3%) controls (P ¼ 0.76) used anticoagulants at any time
during follow-up; 40 of 108 (37.0%) OAG cases and 1348 of
3831 (35.2%) controls (P ¼ 0.69) used PAIs. Amongst the 722
participants using anticoagulants at any time during follow-up,
the median duration of use was 231 days, with a range of 1 to
3823 days; amongst the 1388 participants using PAIs, the
median duration of use was 1112 days, with a range of 7 to
4411 days.
Table 2 presents the final model, adjusting for age, sex,
baseline IOP and IOP-lowering treatment, family history of
glaucoma, and myopia. Participants using anticoagulants and
PAIs had nonsignificant risk reductions with HRs of 0.90 and
0.80, respectively. There was no trend towards a reduced or
increased risk of incident OAG with prolonged anticoagulant
use (HR 0.84 [95% CI, 0.46–1.53; P¼ 0.57] for usage during 2
years or less; HR 1.04 [95% CI, 0.48–2.27; P ¼ 0.92] for usage
during more than 2 years; P value for trend 0.84) or PAI use
(HR 0.78 [95% CI, 0.42–1.45; P¼0.44] for usage during 2 years
or less; HR 0.81 [95% CI, 0.51–1.31; P¼ 0.40] for usage during
more than 2 years; P value for trend 0.59).
Table 3 shows the results of the multiple linear regression
analysis with IOP at follow-up as the dependent variable. As
can be seen in this table, there was a significant IOP-lowering
effect of anticoagulants and a similar but nonsignificant effect
of PAIs.
DISCUSSION
This study did not demonstrate any association between the
use of either anticoagulants or PAIs and incident OAG. Of
interest, the use of anticoagulants seemed to be associated
with a lower IOP.













(n ¼ 2191) P Value
Age 68.4 (7.1) 65.7 (6.8) <0.001 67.3 (6.9) 64.5 (6.6) <0.001
Sex (% female) 49.1 58.7 0.046 55.0 61.1 <0.001
Smoking (%) 33.3 33.4 0.98 32.6 34.1 0.31
Diabetes mellitus (%) 8.4 6.9 0.54 9.2 5.2 <0.001
Angina pectoris (%) 1.9 3.1 0.46 4.7 1.8 <0.001
Atrial fibrillation (%) 2.8 2.1 0.63 3.8 0.8 <0.001
Myocardial infarction (%) 13.2 9.7 0.23 15.1 5.5 <0.001
Heart failure (%) 0.9 1.2 0.81 2.0 0.5 <0.001
Hypertension (%) 52.9 47.1 0.49 57.3 43.5 <0.001
Stroke (%) 2.8 1.2 0.16 2.3 0.5 <0.001
Use of antihypertensive drugs (%) 28.0 26.0 0.63 35.5 18.5 <0.001
Use of statins (%) 0.9 2.1 0.39 32.2 11.3 <0.001
Body mass index (kg/m2) 25.8 (2.9) 26.3 (3.5) 0.12 26.6 (3.5) 26.1 (3.5) <0.001
Total cholesterol (mM) 6.5 (1.1) 6.7 (1.2) 0.17 6.7 (1.2) 6.7 (1.2) 0.82
IOP (mm Hg) 17.3 (4.7) 15.0 (3.1) <0.001 15.1 (3.2) 15.0 (3.2) 0.35
IOP-lowering treatment (%) 15.7 2.3 <0.001 2.5 2.8 0.47
Family history of glaucoma (%) 16.7 8.1 0.002 8.0 8.6 0.50
Myopia 9.5 4.9 0.033 5.1 5.0 0.95
* Antithrombotics include anticoagulants or platelet aggregation inhibitors, or both; data are shown with univariate comparisons (mean [SD]
unless stated otherwise).
TABLE 2. Final Multivariate Model of the Risk of Developing Open-






Anticoagulants 0.90 0.55–1.48 0.69
Platelet aggregation inhibitors 0.80 0.53–1.21 0.28
Age (per year) 1.08 1.05–1.11 <0.001
Sex (female) 0.57 0.39–0.85 0.005
IOP (per mm Hg) 1.12 1.08–1.18 <0.001
IOP treatment 3.24 1.73–6.08 0.002
Family history of glaucoma 1.82 1.06–3.11 0.029
Myopia 2.09 1.08–4.04 0.028
TABLE 3. Multiple Linear Regression Analysis with Intraocular





Anticoagulants 0.31 0.58 to 0.04 0.025
Platelet aggregation inhibitors 0.21 0.44 to 0.008 0.06
Age (year) 0.006 0.021 to 0.010 0.49
Sex (female) 0.30 0.51 to 0.09 0.006
IOP-lowering treatment
at follow-up
1.76 1.34 to 2.18 <0.001
Family history of glaucoma 0.37 0.01 to 0.75 0.054
Myopia 0.60 0.13 to 1.08 0.012
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In a retrospective cohort study performed in a clinical
setting, de Castro et al. examined the effect of ASA on the optic
nerve head as assessed longitudinally with confocal scanning
laser ophthalmoscopy in 76 OAG suspects.11 They did not find
an effect of ASA use after a follow-up of 23 months, which is in
agreement with our findings. Linden et al. conducted a double-
blind, placebo-controlled, randomized cross-over study
amongst 28 patients with ocular hypertension or OAG to
determine the short-term effect of a single dose of 500 mg ASA
on the IOP. There was no statistically significant difference
between the placebo-treated and the ASA-treated patients.9
This is in agreement with our observation that the usage of
PAIs was not associated with the IOP at follow-up. Bell et al.
found, in a retrospective, observational, case-control study
amongst 64 patients undergoing trabeculectomy and 74
controls, an association between ASA use and an increased
frequency of glaucoma surgery, suggesting a harmful effect.10
The major limitation of their study, as reiterated by the authors,
was that they equated the frequency of glaucoma surgery with
the progression of glaucoma. This assumption might have
biased the effect estimate. Although they found a significant
harmful effect, whereas we did not, the 95% CI for ASA use in
their study (1.10–4.79) overlaps with our 95% CI for PAI use
(0.53–1.21).
Although we did not find a significant beneficial or harmful
effect of anticoagulants or PAIs on the incidence of OAG, there
was a significant IOP-lowering effect of anticoagulants. Of
interest, the anticoagulant heparin has been associated with an
increased outflow facility in human and monkey trabecular
meshwork,17–19 providing at least a glimpse of a possible
biological explanation for this unexpected finding. Although
our finding may thus support a hypothesis regarding IOP
regulation, the clinical significance is at most modest, as the R2
was only 0.03 (i.e., the percentage of the IOP at follow-up,
explained by the anticoagulant use in the regression model,
was 3%), and the effect estimate was only approximately0.3
(i.e., those using anticoagulants had—on average—a 0.3 mm
Hg lower IOP than those not using anticoagulants). The
combination of a significant IOP-lowering effect and no effect
on the incidence of OAG might point to a harmful IOP-
independent effect of anticoagulants on OAG. However, with a
12% increase in OAG risk per millimeter HG increase in IOP
(Table 2), the effect of a 0.3 mm Hg lowering of the IOP is
amply within the 95% CI as reported in Table 2. Apart from a
possible biological mechanism explaining the IOP-lowering
effect of anticoagulants, confounding by, for example, the use
of systemic beta-blockers at follow-up could have occurred. If
we adjusted the analysis as presented in Table 3 for beta-
blocker use at follow-up, the IOP-lowering effect of anticoag-
ulants was no longer significant (effect estimate 0.031 mm
Hg; P ¼ 0.78).
In an earlier study, we reported that the use of statins was
associated with a reduced risk of OAG.20 Therefore, the use of
statins may be regarded as a confounding factor in the present
study. In the present study, we corrected—in accordance with
the assumptions of the Cox model—for the use of statins at
baseline. As the use of statins increases rapidly with age, we
explored adjusting for statin use during follow-up as well. No
changes were observed in the HRs of either the anticoagulants
or the PAIs. In another study, we reported that a higher body
mass index was associated with a reduced risk of OAG. No
other lifestyle/socioeconomic factors were associated with
OAG.21 Body mass index appeared not to be a confounding
factor in the current study.
Strengths of our study include its prospective and
population-based design, the large number of participants,
and the long follow-up period. Information bias was prevented
by prospectively and completely automated collection of
pharmacy records of all prescriptions. Although this approach
guarantees accurate prescription data, especially because at
every data download, missing participants were traced,12 a
complete overview of medication prescriptions does not
guarantee that all participants actually took their medication.
In this respect, it is important to mention that the monitoring
of the users of anticoagulants is well organized in The
Netherlands (by means of regular blood sampling and the
provision of personalized dosing schemes). Also, especially the
PAIs that irreversibly block the platelet aggregation (like ASA)
have a long therapeutic half-life (approximately 10 days;
determined by the physiological turnover of platelets). This
should make the effect of these drugs resistant against an
irregular intake. Nevertheless, noncompliance may have
resulted in a too conservative risk estimate, inhibiting the
discovery of small, harmful or protective effects. The usage of
antithrombotics before baseline was not taken into account.
This is an intrinsic limitation of the Rotterdam Study because
the onset of the automated collection of medication data
started at baseline, which may have caused an underestimation
of potential harmful effects. The reason for this bias is that our
outcome measure was incident OAG, which implies that we
excluded participants who had OAG already at baseline
(possibly related to harmful effects of antithrombotics used
before baseline). To explore this potential bias, we repeated
the analysis presented in Table 2 after the exclusion of subjects
already using antithrombotics at baseline. Thirteen of 108
cases and 159 of 3831 controls were excluded. The resulting
HRs were 0.77 (0.43–1.37) for anticoagulants and 0.71 (0.45–
1.11) for PAIs. This suggests that this bias can be ignored.
A possible limitation of this study is potential misclassifica-
tion of exposure. This misclassification will be random because
the outcome is, inextricably, gathered irrespective of exposure
status. To appreciate this approach, it is important to realize
that OAG development often takes more than a decade and
that OAG cannot be detected in the earliest stages. This implies
that some incident OAG cases may already have had
preperimetric changes at baseline,13 whereas some controls
may actually have had preperimetric changes at follow-up.
Some factors slow down or accelerate the disease development
and thus make it less likely or more likely that the disease has
reached a certain stage at a certain point in time (being our
follow-up examination) given that this stage was not yet
reached at baseline. Cumulative exposure stratified into
biologically plausible nominal categories as we used in our
analyses is the best proxy for studying the overall influence of
the use of medication on the rate of glaucoma development
during follow-up.22 Because the exposure misclassification is
random, it will tend to bias the results towards the null
hypothesis. This might have hampered the detection of small
effects in our study.
Another factor that might have hampered the detection of
small effects is the limited number of OAG cases. This is a
limitation of the population-based design. The size of our study
population was determined by the original design of the
Rotterdam Study. The power of the Rotterdam Study was
directed towards common diseases in the elderly, which tend
to have higher prevalences than OAG—despite the fact that
OAG is a very common eye disease. However, once an analysis
has been finished, the confidence intervals of the effect
estimates tell the whole story, and this implies that small
protective or harmful effects could have been overlooked in
our study. However, larger effects, if they would exist, would
have been detected.
In conclusion, to the best of our knowledge, this is the first
study examining the effects of the use of anticoagulants on
OAG, and the first population-based study examining the
effects of PAIs on OAG. We found no clear associations. As
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anticoagulants and PAIs are commonly prescribed in the
elderly, this finding has clinical implications. Our study does
not support withdrawing these drugs, if prescribed for
cardiovascular disease, in patients with OAG. Similarly, our
study does not support the use of these drugs as part of the
treatment of OAG.
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